Presentation of Microbix at the Muskoka Capital Conference

Content of the article

Meetings with growth-oriented investors, September 23-25, 2022

MISSISSAUGA, Ont., Sept. 21, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer and exporter, announces that it will present to investors at the Muskoka Capital Conference, hosted by Capital Event Management Ltd. and hosted at JW Marriott Rosseau Muskoka, Minett, Ontario September 23-25, 2022.

Content of the article

Microbix CEO Cameron Groome and COO Ken Hughes will engage in a series of 18 one-on-one meetings with growth company investors during the formal portion of the conference. The presentation slides they speak to will be posted on Microbix’s website at, along with other business information and its financial disclosures.

Advertisement 2

Content of the article

About Microbix Biosystems
Microbix develops proprietary biological technology solutions for human health and well-being, with over 100 skilled employees and sales approaching C$2.0 million per month. It manufactures a wide range of critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and its laboratory quality assessment products (QAPs™ IVD or RUO test controls) that take support clinical laboratory proficiency testing, enable test development and validation, or help ensure quality in clinical diagnostic workflows. Microbix antigens enable antibody testing from more than 100 international diagnostic companies, while its QAPs are sold to clinical laboratory accreditation bodies, diagnostic companies and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution SpA., Labquality Oy, The Medical Supply Company of Ireland, R-Biopharm AG , SDT Molecular Pte Ltd, Seegene Canada Inc. and Thomas Scientific LLC. Microbix is ​​ISO 9001 and 13485 accredited, registered with the US FDA, registered with the Australian TGA, approved by Health Canada and provides CE marked products.

Advertisement 3

Content of the article

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, including Viral Transport Medium (DxTM™) to stabilize patient samples for molecular diagnostic laboratory testing and Kinlytic® urokinase, a biological thrombolytic drug used to treat blood clots. Microbix is ​​listed on the TSX and OTCQX and is headquartered in Mississauga, Ontario, Canada.

About Capital Event Management Ltd. and the event
Capital Event Management Ltd. produces several investor events each year across North America and the Bahamas. Participants include leading public and private companies, as well as an investor mix of investment advisors, fund managers and high net worth investors. Capital Event’s unique event formats aim to enable principals to build new, lasting relationships that lead to funding, open market support and increased awareness within the investment community. Further information on the Muskoka event is available at

Advertisement 4

Content of the article

Forward-looking information
This press release contains “forward-looking information” as that term is defined under applicable securities laws. Forward-looking information includes, but is not limited to, discussions of Capital Event Management Ltd. and its conferences, Microbix’s business activities and results, its objectives or prospects, risks associated with financial results and stability, development projects such as those mentioned in its corporate presentation, sales to jurisdictions foreign exchange, engineering and construction, production (including cost, quality, quantity and delivery time control), currencies and exchange rates, maintaining profitability and a adequate turnover, or the raising of additional capital on terms acceptable or not at all, and other similar statements regarding anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. All statements are made as of the date of this press release and represent the judgment of the Company as of the date of this new press release, and the Company undertakes no obligation to update or change any forward-looking information.

Please visit or for the latest Microbix news and filings.

For more information, please contact Microbix at:

Cameron Groome,
(905) 361-8910
Jim Currie,
(905) 361-8910
Deborah Honig,
Investor Relations
Adelaide Capital Markets
(647) 203-8793
[email protected]

Copyright © 2022 Microbix Biosystems Inc.
Microbix®DxTM™, kinlytic®and QAPs™ are registered trademarks of Microbix Biosystems Inc.



Postmedia is committed to maintaining a lively yet civil discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to be moderated before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread you follow, or if a user follows you comments. See our Community Guidelines for more information and details on how to adjust your email settings.

Comments are closed.